MI-HARMAN
14.9.2022 15:27:35 CEST | Business Wire | Press release
HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. focused on connected technologies and solutions for automotive, consumer and enterprise markets, today announced the introduction of Ready Care — the latest solution in its expanding portfolio of products designed and built to deliver consumer-focused experiences at an automotive grade. Ready Care is a set of solutions — Cognitive Distraction, Stress-Free Routing, and Personalized Comfort — that can work together or independently to improve safety and reduce driver stress.
Ready Care delivers heightened levels of safety and wellbeing through the integration of several key technologies. In addition to employing cameras that can detect driver drowsiness, Ready Care measures real-time driver cognitive load to identify when potential distractions arise, and then offers tailored intervention strategies to maximize safety. The experience is powered by newly developed machine learning algorithms, which gather and process data from in-vehicle cameras and sensors to monitor a driver’s state. Ready Care can then generate customized in-vehicle cabin prompts to trigger a range of behavioral responses — increasing awareness, alleviating stress, or stimulating relief.
“Safety remains a top concern for consumers when considering a new vehicle purchase, and now, with Ready Care, OEMs can improve vehicle safety in a significant new way,” said Armin Prommersberger, Senior Vice President, Automotive Product Management at HARMAN International. “Ready Care is essentially a co-pilot, spotting when distractions could turn into dangerous situations and intervening to avoid them. For the first time, the vehicle can, in a sense, know what the driver is thinking; this is a game changer. We are incredibly proud of and excited by the impact Ready Care will have for drivers, passengers, and everyone on the road.”
Key features of Ready Care include:
- Eyes and Mind on Road: Ready Care measures both driver eye activity and state of mind. An infra-red global shutter camera with active illumination surveys the driver’s face in low and high light environments to provide real-time data into facial expressions, eye gaze, eyelid openings, and more. The HARMAN Cognitive Distraction feature — a real-time driver visual and cognitive load measurement tool — deciphers when the driver is mentally distracted and can initiate multiple and simultaneous in-cabin vehicle intervention responses. It measures real-time driver cognitive load and separates driving tasks from other mental activities as well as visual and manual distractions to enable tailored intervention strategies that maximize safety.
- Stress-free Routing: Compatible with multiple navigation engines, Ready Care provides an alternate route selection to lower elevated driver stress levels while on the road. Through detecting real-time stress factors like traffic jams or weather and adapting accordingly, this solution helps mitigate the driver’s state of stress or anxiety.
- Personalized Experiences: As all journeys and drivers are unique, Ready Care leverages advanced machine learning technology to provide personalized intervention strategies tailored to the individual and their driving experience. Ready Care delivers closed-loop interventions via an SDK, allowing OEMs and third parties to integrate any vehicle feature or function — such as HVAC control, media content and volume, or seat sensors — into the Ready Care solution. An example could be the advanced technologies offered by Gentherm, the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry.
Ready Care equips OEMs with advanced but meaningful technology to improve driver safety and wellbeing. Automotive manufacturers have the opportunity to incorporate the full set of Ready Care solutions into vehicles or choose specific features to create a more customized solution right for their customers and fleets.
For decades, HARMAN has been uniquely positioned at the intersection of automotive and consumer technology innovation, resulting in meaningful, industry-leading solutions. Through its key consumer and technology brands, deep industry expertise, and robust technology stack, HARMAN is equipped to deliver on the promise of consumer experiences through automotive-grade solutions today.
For more information on HARMAN’s Ready Care solution, visit car.harman.com/experiences/ready-care.
About HARMAN
HARMAN (harman.com) designs and engineers connected products and solutions for automakers, consumers, and enterprises worldwide, including connected car systems, audio and visual products, enterprise automation solutions; and services supporting the Internet of Things. With leading brands including AKG®, Harman Kardon®, Infinity®, JBL®, Lexicon®, Mark Levinson® and Revel®, HARMAN is admired by audiophiles, musicians and the entertainment venues where they perform around the world. More than 50 million automobiles on the road today are equipped with HARMAN audio and connected car systems. Our software services power billions of mobile devices and systems that are connected, integrated and secure across all platforms, from work and home to car and mobile. HARMAN has a workforce of approximately 30,000 people across the Americas, Europe, and Asia. In 2017, HARMAN became a wholly-owned subsidiary of Samsung Electronics Co., Ltd.
© 2022 HARMAN International Industries, Incorporated. All rights reserved. Harman Kardon, Infinity, JBL, Lexicon and Mark Levinson are trademarks of HARMAN International Industries, Incorporated, registered in the United States and/or other countries. AKG is a trademark of AKG Acoustics GmbH, registered in the United States and/or other countries. Features, specifications, and appearance are subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom